CYP3A4 Expression in Breast Cancer and its Association with Risk Factors in Mexican Women

  • Published : 2014.04.30


Background: In Mexico, breast cancer (BCa) is the leading type of cancer in women. Cytochrome P450 (CYP450) is a superfamily of major oxidative enzymes that metabolize carcinogens and many antineoplastic drugs. In addition, these enzymes have influence on tumor development and tumor response to therapy. In this report, we analyzed the protein expression in patients with BCa and in healthy women. Links with some clinic-pathological characteristic were also assessed. Materials and Methods: Immunohistochemical analyses were conducted on 48 sets of human breast tumors and normal breast tissues enrolled in Hospital Militar de Especialidades de la Mujer y Neonatologia and Hospital Central Militar, respectively, during the time period from 2010 to 2011. Informed consent was obtained from all participants. Statistical analysis was performed using ${\chi}^2$ or Fisher exact tests to estimate associations and the Mann Whitney U test for comparison of group means. Results: We found a significant CYP3A4 overexpression in BCa stroma and gland regions in comparison with healthy tissue. A significant association between protein expression with smoking, alcoholism and hormonal contraceptives use was also observed. Additionally, we observed estrogen receptor (ER) and progesterone receptor (PR) positive association in BCa. Conclusions: We suggest that CYP3A4 expression promotes BCa development and can be used in the prediction of tumor response to different treatments. One therapeutic approach may thus be to block CYP3A4 function.


  1. Wang-Rodriguez J, Cross K, Gallagher S, et al (2002). Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol, 15, 853-61.
  2. Weiss J, Haefeli WE (2011). Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol, 68, 1093-8.
  3. World Health Organization (2012).
  4. Xing MY, Xu SZ, Shen P (2014). Effect of low-fat diet on breast cancer survival:a meta-analysis. Asian Pac J Cancer Prev, 15, 1141-4.
  5. Zheng W, Jin F, Dunning LA, et al (2001). Epidemiological study of urinary 6beta-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 237-42.
  6. Zhu BT, Conney AH (1998b). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res, 58, 2269-77.
  7. Ragin CC, Langevin S, Rubin S, et al (2010). Review of studies on metabolic genes and cancer in populations of African descent. Genet Med, 12, 12-8.
  8. Miyoshi Y, Taguchi T, Kim SJ, et al (2005). Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer, 12, 11-5.
  9. Nelson HD, Zakher B, Cantor A, et al (2012). Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med, 15, 635-48.
  10. Niwa T, Yabusaki Y, Honma K, et al (1998). Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica, 28, 539-47.
  11. Shapiro C, Recht A (2001). Side effects of adjuvant treatment of breast cancer. N Engl J Med, 344, 1997-2008.
  12. Shou M, Korzekwa KR, Brooks EN, et al (1997). Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis, 18, 207-14.
  13. Sistema Nacional de Informacion en Salud (2012).
  14. Takahara T, Nitta H, Hasegawa Y, et al (2011). Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor. Transplant Proc, 4, 2800-5.
  15. Torres-Mejia G, Cupul-Uicab LA, Allen B, et al (2005). Comparative study of correlates of early age at menarche among Mexican and Egyptian adolescents. Am J Hum Biol, 17, 54-8.
  16. Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, et al (2007). RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res, 27, 4443-50.
  17. Lopez-Carrillo L, Bravo-Alvarado J, Poblano-Verastegui O, et al (1997). Reproductive determinants of breast cancer in Mexican women. Ann N Y Acad Sci, 837, 537-50.
  18. Kim SY, Suzuki N, Santosh Laxmi YR, et al (2003). Alphahydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol, 16, 1138-44.
  19. Knaul FM, Lopez Carrillo L, Lazcano Ponce E, et al (2009). Cancer de mama: un reto para la sociedad y los sistemas de salud. Salud Publica Mex, 51, 135-7.
  20. LIatrakis G, Iavazzo C, Zervoudis S, et al (2011). The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients. Clin Exp Obstet Gynecol, 38, 225-7.
  21. Lopez-Carrillo L (2003). El cancer mamario: epidemiologia y prevencion. In: Tamayo RP. El cancer en Mexico. Mexico, D.F.: El Colegio Nacional, 443-56.
  22. Lown KS, Bailey DG, Fontana RJ, et al (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest, 99, 2545-53.
  23. Mc Fadyen MCE, Melvin WT, Murray GI (2004). Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther, 3, 363-71.
  24. Mendez -Estrada RO, Valencia M, Melendez Torres JM (2006). Menarche age in teenagers of the Northwest of Mexico. Arch Latinoam Nutr, 5, 1-3.
  25. Michael M, Doherty MM (2007). Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug, 3, 786-03.
  26. Mitra R, Gou Z, Milani M, et al (2011). CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducig nuclear translocation of phospho-Stat3 through biosynthesis of (+)-14, 15-epoxyeicosatrienoin acid (EET). J Biol Chem, 286, 17543-59.
  27. Garrido-Latorre EC, Lazcano-Ponce L, Lopez-Carrillo M, et al (1996). Age of natural menopause among women in Mexico city. Int J Gynaecol Obstet, 53, 159-66.
  28. Canchola AJ, Anton-Culver H, Bernstein L, et al (2012). Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control, [Epub ahead of print].
  29. Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, et al (2012). CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 837-46.
  30. Chu W, Fyles A (2007). Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis, 28, 2139-42.
  31. Guengerich FP (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1-17.
  32. Haas S, Pierl C, Harth V, et al (2006). Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer, 119, 1785-91.
  33. Hassan BA, Yusoff ZB (2011). Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 12, 185-91.
  34. Huang Z, Fasco MJ, Figge HL, et al (1996). Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos, 24, 899-05.
  35. Jacquemier JD, Penault-Llorca FM, Bertucci F, et al (1998). Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol, 184, 130-5.<130::AID-PATH19>3.0.CO;2-W
  36. Bruno RD, Njar VC (2007). Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem, 15, 5047-60.
  37. Bandala C, Floriano-Sanchez E, Cardenas-Rodriguez N, Lopez-Cruz J, Lara-Padilla E (2012). RNA Expression of cytochrome P450 in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 2647-53.
  38. Basseville A, Preisser L, de CarneTrecesson S, et al (2011). Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer, 10, 80-92.
  39. Blacam C, Ogunleye AA, Momoh AO, et al (2012). High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national surgical quality improvement program database. Ann Surg, 255, 551-5.

Cited by

  1. Overexpression of Hiwi Promotes Growth of Human Breast Cancer Cells vol.15, pp.18, 2014,
  2. Breast Cancer Screening Barriers from the Womans Perspective: a Meta-synthesis vol.16, pp.8, 2015,
  3. Association of Histopathological Markers with Clinico-Pathological Factors in Mexican Women with Breast Cancer vol.16, pp.18, 2016,
  4. HER-2 Positive Breast Cancer - a Mini-Review vol.17, pp.4, 2016,
  5. Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them vol.37, pp.2-3, 2018,